1. Home
  2. XAIR vs GNPX Comparison

XAIR vs GNPX Comparison

Compare XAIR & GNPX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo Beyond Air Inc.

XAIR

Beyond Air Inc.

HOLD

Current Price

$1.35

Market Cap

10.5M

Sector

Health Care

ML Signal

HOLD

Logo Genprex Inc.

GNPX

Genprex Inc.

HOLD

Current Price

$2.97

Market Cap

10.8M

Sector

Health Care

ML Signal

HOLD

Company Overview

Basic Information
Metric
XAIR
GNPX
Founded
2011
2009
Country
United States
United States
Employees
N/A
N/A
Industry
Medical/Dental Instruments
Biotechnology: Pharmaceutical Preparations
Sector
Health Care
Health Care
Exchange
Nasdaq
Nasdaq
Market Cap
10.5M
10.8M
IPO Year
N/A
2018

Fundamental Metrics

Financial Performance
Metric
XAIR
GNPX
Price
$1.35
$2.97
Analyst Decision
Strong Buy
Analyst Count
1
0
Target Price
$11.00
N/A
AVG Volume (30 Days)
1.2M
293.4K
Earning Date
11-10-2025
11-14-2025
Dividend Yield
N/A
N/A
EPS Growth
N/A
N/A
EPS
N/A
N/A
Revenue
$5,802,000.00
N/A
Revenue This Year
$261.11
N/A
Revenue Next Year
$151.82
N/A
P/E Ratio
N/A
N/A
Revenue Growth
147.74
N/A
52 Week Low
$1.19
$2.77
52 Week High
$11.56
$63.00

Technical Indicators

Market Signals
Indicator
XAIR
GNPX
Relative Strength Index (RSI) 30.99 42.93
Support Level $1.19 $2.77
Resistance Level $1.38 $5.00
Average True Range (ATR) 0.11 0.48
MACD 0.01 -0.27
Stochastic Oscillator 20.15 8.07

Price Performance

Historical Comparison
XAIR
GNPX

About XAIR Beyond Air Inc.

Beyond Air Inc is a commercial-stage medical device and biopharmaceutical company that develops a Nitric Oxide (NO) Generator and Delivery System that uses NO generated from ambient air and delivers precise amounts of NO to the lungs for the potential treatment of respiratory and other diseases. The firm is applying its therapeutic expertise to develop treatments for pulmonary hypertension, in addition to treatments for lower respiratory tract infections.

About GNPX Genprex Inc.

Genprex Inc is a clinical-stage gene therapy company focused on developing life-changing therapies for patients with cancer and diabetes. Its technologies are designed to administer disease-fighting genes to provide new therapies for large patient populations with cancer and diabetes who currently have limited treatment options. Genprex's oncology program utilizes its systemic, non-viral Oncoprex Delivery System which encapsulates the gene-expressing plasmids using lipid-based nanoparticles in a lipoplex form. The company's product candidate, Reqorsa Immunogene Therapy (quaratusugene ozeplasmid), is being evaluated in three clinical trials as a treatment for NSCLC and SCLC.

Share on Social Networks: